Skinvisible, Inc. (OTCBB: SKVI) Four Strong Sources of Revenue


Skinvisible, Inc. (OTCBB: SKVI) StockGuru SKVI Profile

Skinvisible, Inc. develops innovative polymer delivery vehicles and related compositions that hold active ingredients on the skin for extended periods of time when applied topically. The Invisicare® polymer delivery vehicle has multiple applications which include enhanced, patent protected dermatology and healthcare products. This is a strong point in terms of revenue.
The Invisicare® polymer delivery vehicle has multiple, worldwide uses protected by patents with the long term ability to generate revenue with BOTH licensing and royalty opportunities. This means a repetitive long term revenue stream.

This week we have focused on SKVI’s broad geographic range supported by patents. With the additional patent granted in Hong Kong there are now nine seven patents approved, including three in the US, and internationally in China, India, Australia, Japan, Hong Kong, and Korea.

  • Nine Seven approved patents including the US, India, Australia, China and Japan
  • Nine U.S. patents pending
  • 34 international PCTs

FIRST: Take a good look at ALL SKVI Revenue Streams:

Skinvisible has four sources of revenue:

1. Licensing Fees
2. Royalties from Licensed Polymers
3. Research and Development Fees
4. Sales of Polymers

SECOND: Take a good look at all the applications for which the patented polymer deliver system can be used.

Invisicare® applications include enhanced, patent protected dermatology and healthcare products including:

Treat acne
Skin cancers
Eczema
Fungal infections
Inflammation
Warts
Dermatitis
Sunscreens
Anti-aging products
Alcohol-free hand sanitizing lotions
Pre-surgical preparations
Various other medical treatments

What this means is with SKVI you have a product with a broad application — Invisicare® protected by international patents and able to continually generate revenue from BOTH licensing agreements and ON GOING royalties.
Polymer Formulations for Multiple Products

On an ongoing basis, Skinvisible develops polymer formulations that can successfully be incorporated into other products.

THIRD: Look at ALL the products that successfully incorporate Invisicare® to date include:

Antimicrobial hand sanitizer lotions
Suncare products
Skincare moisturizers
Sunless tanning products
Multiple dermatology products for various skin disorders

SKVI has a strong competitive advantage: Invisicare’s® products bind to the skin for 4 hours and more, while resisting wash-off and rub-off. It also enhances the efficacy of ingredients, reduces irritation and can reduce costs.

Fourth: Look at Invisicare® Advantages

In terms of the competition Invisicare® has other advantages:

Displays superior skin adherence for extended time periods
Non-occlusive yet resists water wash-off, respiration and perspiration
Increased efficacy of active ingredients
Allows for lower use levels of actives with increased persistence of effect
Offers advantage of controlled and/or sustained time-release
Highly compatible with a variety of actives and bases
Easy to emulsify
Formulates well at a cream, lotion, or spray viscosity
Non-irritating emulsion dries quickly with no greasy after-feel
Non-occlusive film forms protective barrier against environmental irritants
Broad polymer selection to meet application requirements
Offers “Life Cycle” management to core products with potential for new patent
Simplified manufacturing process

Now — add up Points One through Four:

Point One – Revenue Streams
Point Two – Applications for Invisicare®
Point Three: Products that Incorporate Invisicare®
Point Four: Invisicare Advantages®

You have a long term, powerful pharmaceutical biotech company claiming its position on the world stage; that’s SKVI!

Skinvisible, Inc. / Skinvisible Pharmaceuticals, Inc.
6320 S. Sandhill Road, Suite 10
Las Vegas, Nevada, 89120 U.S.A.
Phone:
702.433.7154
Fax:
702.433.7192
Email:
info@skinvisible.com
Phone:
801.485.7978
Fax:
801.466.6877

About Invisicare: Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare.

Pentony Enterprises LLC is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010. The company has agreed to pay us five thousand dollars per month in cash for the period of six months, totaling thirty thousand USD. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. To further clarify, we will not be buying or selling shares for the period of July 12, 2010 through January 12, 2011. We hold no shares and will not be receiving further compensation that is share related during this period. Pentony Enterprises is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Left Menu Icon
Right Menu Icon